Who are we?
A global leader in microRNA-enabled diagnostics
Founded in 2014, MiRXES is a Singapore-based biotech company that specializes in microRNA technology and develops microRNA-enabled molecular diagnostics for early detection of cancer, cardiovascular and metabolic diseases, and infectious diseases. Our proprietary and versatile technology platform enables us to design preventive and precision diagnostic solutions for the world, covering a variety of industries from medical and pharmaceutical to agri-tech and vet-tech.
In 2019, we became the first company worldwide to bring to market an approved diagnostic test for early gastric cancer detection with its launch in Singapore. In 2020, we brought to market a COVID-19 RT-PCR test kit that was first to receive provisional authorization in Singapore, and is now used in 13 Singapore hospitals and labs, and more than 30 countries globally.
Why do we exist?
To save and improve lives through early detection
How will we achieve our goal?
Discover, develop, and deliver Accurate, Actionable, and Affordable diagnostic solutions, to enable the early detection of cancers and other diseases.
What does this mean for you?
Greater peace of mind, timely life-saving care, and improved quality of life.